Increasing importance of European lineages in seeding the hepatitis C virus subtype 1a epidemic in Spain.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
Feb 2019
Historique:
entrez: 14 3 2019
pubmed: 14 3 2019
medline: 10 7 2020
Statut: ppublish

Résumé

BackgroundReducing the burden of the hepatitis C virus (HCV) requires large-scale deployment of intervention programmes, which can be informed by the dynamic pattern of HCV spread. In Spain, ongoing transmission of HCV is mostly fuelled by people who inject drugs (PWID) infected with subtype 1a (HCV1a).AimOur aim was to map how infections spread within and between populations, which could help formulate more effective intervention programmes to halt the HCV1a epidemic in Spain.MethodsEpidemiological links between HCV1a viruses from a convenience sample of 283 patients in Spain, mostly PWID, collected between 2014 and 2016, and 1,317, 1,291 and 1,009 samples collected abroad between 1989 and 2016 were reconstructed using sequences covering the NS3, NS5A and NS5B genes. To efficiently do so, fast maximum likelihood-based tree estimation was coupled to a flexible Bayesian discrete phylogeographic inference method.ResultsThe transmission network structure of the Spanish HCV1a epidemic was shaped by continuous seeding of HCV1a into Spain, almost exclusively from North America and European countries. The latter became increasingly relevant and have dominated in recent times. Export from Spain to other countries in Europe was also strongly supported, although Spain was a net sink for European HCV1a lineages. Spatial reconstructions showed that the epidemic in Spain is diffuse, without large, dominant within-country networks.ConclusionTo boost the effectiveness of local intervention efforts, concerted supra-national strategies to control HCV1a transmission are needed, with a strong focus on the most important drivers of ongoing transmission, i.e. PWID and other high-risk populations.

Identifiants

pubmed: 30862327
doi: 10.2807/1560-7917.ES.2019.24.9.1800227
pmc: PMC6402173
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

AIDS. 2000 Jan 7;14(1):75-83
pubmed: 10714570
J Infect Dis. 2002 Nov 1;186(9):1212-21
pubmed: 12402190
J Infect Dis. 2004 Jan 15;189(2):292-302
pubmed: 14722895
J Virol. 2007 Dec;81(23):13050-6
pubmed: 17898057
Philos Trans R Soc Lond B Biol Sci. 2008 Dec 27;363(1512):3985-95
pubmed: 18852111
PLoS Med. 2009 Dec;6(12):e1000198
pubmed: 20041120
J Gen Virol. 2012 Apr;93(Pt 4):889-99
pubmed: 22190015
Bioinformatics. 2014 Aug 15;30(16):2272-9
pubmed: 24753484
Infect Genet Evol. 2014 Aug;26:32-40
pubmed: 24820342
J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):181-95
pubmed: 24977473
PLoS Genet. 2015 Aug 12;11(8):e1005421
pubmed: 26267488
J Virol. 2015 Dec;89(24):12341-8
pubmed: 26423943
Proc Biol Sci. 2015 Dec 22;282(1821):20142878
pubmed: 26702033
J Hepatol. 2016 Jun;64(6):1247-55
pubmed: 26924451
Open Forum Infect Dis. 2016 Mar 11;3(2):ofw059
pubmed: 27186584
Mol Biol Evol. 2016 Aug;33(8):2167-9
pubmed: 27189542
J Clin Virol. 2016 Aug;81:82-9
pubmed: 27367545
J Hepatol. 2016 Dec;65(6):1094-1103
pubmed: 27520879
J Infect Dis. 2016 Nov 1;214(9):1383-1389
pubmed: 27571901
J Viral Hepat. 2017 Sep;24(9):725-732
pubmed: 28248445
BMC Evol Biol. 2017 Mar 7;17(1):70
pubmed: 28270091
Sci Rep. 2017 Mar 21;7:44947
pubmed: 28322313
Germs. 2017 Mar 1;7(1):40-44
pubmed: 28331841
Infect Genet Evol. 2017 Aug;52:100-105
pubmed: 28427935
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):514-522
pubmed: 29337848
PLoS One. 2018 Jul 25;13(7):e0201268
pubmed: 30044871
Clin Infect Dis. 2018 Oct 30;67(10):1477-1492
pubmed: 30215672
Curr Opin Virol. 2018 Aug;31:24-32
pubmed: 30248578
Bioinformatics. 2018 Oct 8;:null
pubmed: 30295730

Auteurs

Ana Belen Pérez (AB)

Department of Microbiology, Institute of Bio Sanitary Research (IBIS), AIDS Research Network, University Hospital of Granada, Granada, Spain.
These authors contributed equally to the article.

Bram Vrancken (B)

These authors contributed equally to the article.
KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Evolutionary and Computational Virology, Leuven, Belgium.

Natalia Chueca (N)

Department of Microbiology, Institute of Bio Sanitary Research (IBIS), AIDS Research Network, University Hospital of Granada, Granada, Spain.

Antonio Aguilera (A)

Department of Microbiology, University Hospital of Santiago, Santiago de Compostela, Spain.

Gabriel Reina (G)

Department of Microbiology, University Hospital of Navarra, Institute for Health Research (IdisNA), Pamplona, Spain.

Miguel García-Del Toro (M)

Unit of Infectious Diseases, General Hospital of Valencia, Valencia.

Francisco Vera (F)

Unit of Infectious Diseases, Internal Medicine, General Hospital of Rosell, Cartagena, Murcia, Spain.

Miguel Angel Von Wichman (MA)

Unit of Infectious Diseases, Hospital Universitario de San Sebastian, San Sebastian, Spain.

Juan Ignacio Arenas (JI)

Unit of Infectious Diseases, Hospital Universitario de San Sebastian, San Sebastian, Spain.

Francisco Téllez (F)

Unit of Infectious Diseases and Microbiology, University Hospital of Puerto Real, Cádiz, Spain.

Juan A Pineda (JA)

Unit of Infectious Diseases, University Hospital of Valme, Sevilla, Spain (J.A. Pineda).

Mohamed Omar (M)

University Hospital of Jaen, Jaen, Spain.

Enrique Bernal (E)

Unit of Infectious Diseases, General University Hospital, Murcia, Spain.

Antonio Rivero-Juárez (A)

Unit of Infectious Diseases, University Hospital Reina Sofía of Córdoba, Maimonides Institute of Biomedical Research of Córdoba, University of Córdoba, Córdoba, Spain.

Elisa Fernández-Fuertes (E)

Unit of Tropical Medicine, Hospital of Poniente, El Ejido, Almería, Spain.

Alberto de la Iglesia (A)

Department of Microbiology, Hospital Infanta Elena of Huelva, Huelva, Spain.

Juan Manuel Pascasio (JM)

Clinical Management Unit of Digestive Diseases, University Hospital of Virgen del Rocío, Sevilla, Spain.

Philippe Lemey (P)

KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Evolutionary and Computational Virology, Leuven, Belgium.

Féderico Garcia (F)

Department of Microbiology, Institute of Bio Sanitary Research (IBIS), AIDS Research Network, University Hospital of Granada, Granada, Spain.
These authors contributed equally to the article.

Lize Cuypers (L)

KU Leuven, Department of Microbiology and Immunology, Rega Institute for Medical Research, Laboratory of Clinical and Epidemiological Virology, Leuven, Belgium.
These authors contributed equally to the article.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH